Ozempic craze: Novo Nordisk invests $4.1B in US to expand manufacturing
What will Novo Nordisk's expanded facilities primarily produce?
Novo Nordisk's expanded facilities will primarily produce its highly sought-after weight-loss drugs, Wegovy and Ozempic. The investment will increase production capacity and help meet the growing global demand for these life-changing medicines.
How many new jobs will the expansion create?
The expansion will create 1,000 new jobs in the region, nearly doubling the current number of Novo Nordisk employees working there.
How much will the obesity drug market be worth by 2030?
The obesity drug market is projected to reach $105 billion by 2030, according to Morgan Stanley. This growth is driven by factors such as increasing obesity rates, the effectiveness of new drug classes like GLP-1 receptor agonists, and expanding insurance coverage for obesity treatments. Some analysts even predict the market could reach as high as $144 billion over the next six years.